PNPLA3 and metabolic dysfunction-associated steatotic liver disease: Over the last few years, oligonucleotide-based therapies such as small-interfering RNA (siRNA) and antisense oligonucleotide (ASO) have been developed for the treatment of MASLD by reducing the expression of the PNPLA3 gene [113].